Jin Sun Ryu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jin Sun Ryu has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Jeong-Ho Seok
Institute of Behavioral Science in Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
6 shared publications - HyunKyung Shin
Research Institute of Minds.AI, Co. Ltd., Seoul, Republic of Korea
3 shared publications - Sooah Jang
Research Institute of Minds.AI, Co. Ltd., Seoul, Republic of Korea
3 shared publications - Byung Moon Kim
Department of Radiology, Yonsei University College of Medicine, Seoul, Korea
2 shared publications - Jooyoung Oh
Department of Psychiatry, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
2 shared publications - Ju-Yeal Lee
Research Institute, MINDSAI, Co. Ltd., Seoul, Korea
2 shared publications
Latest Publications
- Open Access
- 13 November 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Efficacy and Usability of a Virtual Reality-Based Cognitive Behavioral Therapy Program (CHEEU. Forest N) for Patients with Major Depressive Disorder: A Randomized, Non-inferiority Confirmatory Trial (Preprint)
BACKGROUND Major depressive disorder (MDD) poses a substantial global health burden, with a high suicide risk and limited treatment accessibility. Although cognitive behavioral therapy (CBT) shows robust efficacy, practical barriers, including therapist availability and time constraints, limit its implementation. Virtual reality (VR)-based interventions offer an immersive and accessible alternative. However, rigorous evidence for VR-based CBT for depression remains limited. OBJECTIVE To evaluate the efficacy and usability of CHEEU. Forest N, a VR-based CBT program integrating components of mindfulness-based cognitive, mentalization-based, and dialectical behavior therapies, compared with standard pharmacotherapy in patients with MDD. METHODS This multicenter, randomized, parallel-group, assessor-blinded, non-inferiority confirmatory trial enrolled 134 adults aged between 19 and 55 years who met the DSM-5 criteria for MDD with Patient Health Questionnaire-9 scores ≥7 and moderate suicidality. The participants were randomized 1:1 to receive 6 weekly VR-based CBT sessions (VR group, n=67) or standard antidepressant treatment with brief clinical interviews (treatment-as-usual; TAU group, n=67). The primary outcome was the change in the Korean version of the Quick Inventory of Depressive Symptomatology-Clinician-Rated (K-QIDS-C) scores from baseline to post-treatment (week 6), with a non-inferiority comparison. The secondary outcomes included self-reported depression, anxiety, stress, suicidality, quality of life, presence, and usability. The per-protocol analysis included 116 participants (58 in each group). RESULTS Both groups demonstrated a significant reduction in the severity of their depressive symptoms. The adjusted between-group difference in K-QIDS-C scores was 0.13 points (SE=0.91, 95% CI: –1.66 to 1.93, p=.883), confirming non-inferiority of VR to TAU (upper CI bound 1.93<5.0). Response rates were comparable between the VR (44.8%) and TAU (43.1%) groups (χ²=0.04, p=.852), as were the remission rates (25.9% vs. 27.6%, χ²=0.04, p=.834). For suicidality, 50% of the VR participants achieved remission compared with 43% in TAU (χ²=0.55, p=.457). No significant between-group differences emerged for the secondary outcomes, including anxiety, stress, or quality of life. Usability ratings were high (mean composite score 3.73±0.62/5.0), with participants reporting increased depression literacy (7.43±1.94/10) and willingness to recommend the program (7.47±2.01/10). Simulator sickness decreased significantly with repeated exposure. Baseline presence was correlated with usability (r=0.46, p<.001) but not with clinical outcomes. No serious adverse events occurred. CONCLUSIONS The VR-based CBT intervention demonstrated therapeutic efficacy equivalent to that of standard pharmacotherapy in treating depression, particularly in reducing suicidal ideation and increasing user satisfaction. These findings support VR-based digital therapeutics as safe, effective, and accessible alternatives or adjunctive treatment options for depression, warranting further investigation of long-term outcomes. CLINICALTRIAL This trial was registered with the Clinical Research Information Service (KCT0009868).
- 13 November 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessEfficacy and Usability of a Virtual Reality-Based Cognitive Behavioral Therapy Program (CHEEU. Forest N) for Patients with Major Depressive Disorder: A Randomized, Non-inferiority Confirmatory Trial (Preprint)
BACKGROUND Major depressive disorder (MDD) poses a substantial global health burden, with a high suicide risk and limited treatment accessibility. Although cognitive behavioral therapy (CBT) shows robust efficacy, practical barriers, including therapist availability and time constraints, limit its implementation. Virtual reality (VR)-based interventions offer an immersive and accessible alternative. However, rigorous evidence for VR-based CBT for depression remains limited. OBJECTIVE To evaluate the efficacy and usability of CHEEU. Forest N, a VR-based CBT program integrating components of mindfulness-based cognitive, mentalization-based, and dialectical behavior therapies, compared with standard pharmacotherapy in patients with MDD. METHODS This multicenter, randomized, parallel-group, assessor-blinded, non-inferiority confirmatory trial enrolled 134 adults aged between 19 and 55 years who met the DSM-5 criteria for MDD with Patient Health Questionnaire-9 scores ≥7 and moderate suicidality. The participants were randomized 1:1 to receive 6 weekly VR-based CBT sessions (VR group, n=67) or standard antidepressant treatment with brief clinical interviews (treatment-as-usual; TAU group, n=67). The primary outcome was the change in the Korean version of the Quick Inventory of Depressive Symptomatology-Clinician-Rated (K-QIDS-C) scores from baseline to post-treatment (week 6), with a non-inferiority comparison. The secondary outcomes included self-reported depression, anxiety, stress, suicidality, quality of life, presence, and usability. The per-protocol analysis included 116 participants (58 in each group). RESULTS Both groups demonstrated a significant reduction in the severity of their depressive symptoms. The adjusted between-group difference in K-QIDS-C scores was 0.13 points (SE=0.91, 95% CI: –1.66 to 1.93, p=.883), confirming non-inferiority of VR to TAU (upper CI bound 1.93<5.0). Response rates were comparable between the VR (44.8%) and TAU (43.1%) groups (χ²=0.04, p=.852), as were the remission rates (25.9% vs. 27.6%, χ²=0.04, p=.834). For suicidality, 50% of the VR participants achieved remission compared with 43% in TAU (χ²=0.55, p=.457). No significant between-group differences emerged for the secondary outcomes, including anxiety, stress, or quality of life. Usability ratings were high (mean composite score 3.73±0.62/5.0), with participants reporting increased depression literacy (7.43±1.94/10) and willingness to recommend the program (7.47±2.01/10). Simulator sickness decreased significantly with repeated exposure. Baseline presence was correlated with usability (r=0.46, p<.001) but not with clinical outcomes. No serious adverse events occurred. CONCLUSIONS The VR-based CBT intervention demonstrated therapeutic efficacy equivalent to that of standard pharmacotherapy in treating depression, particularly in reducing suicidal ideation and increasing user satisfaction. These findings support VR-based digital therapeutics as safe, effective, and accessible alternatives or adjunctive treatment options for depression, warranting further investigation of long-term outcomes. CLINICALTRIAL This trial was registered with the Clinical Research Information Service (KCT0009868).
- Open Access
- 25 June 2025
- Published by Korean Neuropsychiatric Association in Psychiatry Investigation
- Vol. 22 (6) , 660-667
Psychological Impact and Differences in Child and Adolescent Victims of Sexual Violence in South Korea: Using Data From a Sunflower Center in South Korea From 2015 to 2022
Objective Sexual violence against children and adolescents is a serious social problem. The characteristics of child and adolescent victims differ based on their varying developmental processes. Therefore, we conducted a comparative analysis to assess the same.Methods Data were collected from victims of sexual violence between 2015 and 2022, from a Sunflower Center, which is a government-sponsored center for victims of sexual violence. The participants were classified into two groups: children under age 12 and adolescents over age 13 years. To compare and analyze data, we collected demographic information, information related to victimization events, and scores on the Children’s Depression Inventory, Revised Children’s Manifest Anxiety Scale, and Children’s Revised Impact of Event Scale. A descriptive analysis, χ 2 test, Fisher’s exact test, and multiple logistic regression analysis were performed.Results Among 255 participants, 95 and 160 were children and adolescents, respectively. The percentage of forced molestation was significantly higher in children at 71.6% (n=68, p<0.001). Children included significantly more male participants (14.7%, n=14, p=0.007) than adolescents. Significant differences were observed between children and adolescents’ depression, anxiety, and posttraumatic stress scores (p<0.001). Compared with children, adolescents demonstrated an adjusted odds ratio of 2.9 for high post-traumatic stress symptoms, 2.26 for high depressive symptoms, and 3.0 for high anxiety symptoms.Conclusion We identified differences in the characteristics of sexual violence victims, particularly children and adolescents, and found that adolescent victims were more vulnerable to the psychological repercussions of abuse than child victims.
- 25 June 2025
- Published by Korean Neuropsychiatric Association in Psychiatry Investigation
- Vol. 22 (6) , 660-667
Open AccessPsychological Impact and Differences in Child and Adolescent Victims of Sexual Violence in South Korea: Using Data From a Sunflower Center in South Korea From 2015 to 2022
Objective Sexual violence against children and adolescents is a serious social problem. The characteristics of child and adolescent victims differ based on their varying developmental processes. Therefore, we conducted a comparative analysis to assess the same.Methods Data were collected from victims of sexual violence between 2015 and 2022, from a Sunflower Center, which is a government-sponsored center for victims of sexual violence. The participants were classified into two groups: children under age 12 and adolescents over age 13 years. To compare and analyze data, we collected demographic information, information related to victimization events, and scores on the Children’s Depression Inventory, Revised Children’s Manifest Anxiety Scale, and Children’s Revised Impact of Event Scale. A descriptive analysis, χ 2 test, Fisher’s exact test, and multiple logistic regression analysis were performed.Results Among 255 participants, 95 and 160 were children and adolescents, respectively. The percentage of forced molestation was significantly higher in children at 71.6% (n=68, p<0.001). Children included significantly more male participants (14.7%, n=14, p=0.007) than adolescents. Significant differences were observed between children and adolescents’ depression, anxiety, and posttraumatic stress scores (p<0.001). Compared with children, adolescents demonstrated an adjusted odds ratio of 2.9 for high post-traumatic stress symptoms, 2.26 for high depressive symptoms, and 3.0 for high anxiety symptoms.Conclusion We identified differences in the characteristics of sexual violence victims, particularly children and adolescents, and found that adolescent victims were more vulnerable to the psychological repercussions of abuse than child victims.
- Open Access
- 25 April 2025
- Published by Korean Neuropsychiatric Association in Psychiatry Investigation
- Vol. 22 (4) , 412-423
Machine Learning Prediction of Attachment Type From Bio-Psychological Factors in Patients With Depression
Objective Adult attachment style is linked to how an individual responds to threats or stress and is known to be related to the onset of psychiatric symptoms such as depression. However, as the current assessment of attachment type mainly relies on self-report questionnaires and can be prone to bias, there is a need to incorporate physiological factors along with psychological symptoms and history in this process. We aimed to predict the measurement of two important types of adult attachment with heart rate variability (HRV), early life stress experience, and subjective psychiatric symptoms.Methods Five hundred eighty-two subjects with depressive disorder were recruited retrospectively from January 2015 to June 2021. The experience of early life stress and psychiatric symptoms were collected, and HRV measures were obtained as input for an ensembled Voting Regressor model of machine learning-based regression models, including linear regression, ElasticNet, Support Vector Machine (SVM), Random Forest, and Extreme Gradient Boosting (XGBoost).Results Model performances evaluated with R-squared score averaged across 30 seeds were 0.377 and 0.188 for anxious- and avoidant-attachment, respectively. Mean absolute error averaged to 13.251 and 12.083, respectively. Shapley value importance analysis indicated that for both attachment types, the most important feature was the trait-anxiety, followed by emotional abuse, state-anxiety or self-reported depressive symptoms, and fear or helplessness felt in the moment of an early life stressor.Conclusion Our results provide the evidence base that may be utilized in clinical settings to predict the degree of attachment type using bio-psychological factors.
- 25 April 2025
- Published by Korean Neuropsychiatric Association in Psychiatry Investigation
- Vol. 22 (4) , 412-423
Open AccessMachine Learning Prediction of Attachment Type From Bio-Psychological Factors in Patients With Depression
Objective Adult attachment style is linked to how an individual responds to threats or stress and is known to be related to the onset of psychiatric symptoms such as depression. However, as the current assessment of attachment type mainly relies on self-report questionnaires and can be prone to bias, there is a need to incorporate physiological factors along with psychological symptoms and history in this process. We aimed to predict the measurement of two important types of adult attachment with heart rate variability (HRV), early life stress experience, and subjective psychiatric symptoms.Methods Five hundred eighty-two subjects with depressive disorder were recruited retrospectively from January 2015 to June 2021. The experience of early life stress and psychiatric symptoms were collected, and HRV measures were obtained as input for an ensembled Voting Regressor model of machine learning-based regression models, including linear regression, ElasticNet, Support Vector Machine (SVM), Random Forest, and Extreme Gradient Boosting (XGBoost).Results Model performances evaluated with R-squared score averaged across 30 seeds were 0.377 and 0.188 for anxious- and avoidant-attachment, respectively. Mean absolute error averaged to 13.251 and 12.083, respectively. Shapley value importance analysis indicated that for both attachment types, the most important feature was the trait-anxiety, followed by emotional abuse, state-anxiety or self-reported depressive symptoms, and fear or helplessness felt in the moment of an early life stressor.Conclusion Our results provide the evidence base that may be utilized in clinical settings to predict the degree of attachment type using bio-psychological factors.
- Open Access
- 25 August 2024
- Published by Korean Neuropsychiatric Association in Psychiatry Investigation
- Vol. 21 (8) , 885-896
Effect of Low-Intensity Transcranial Focused Ultrasound Stimulation in Patients With Major Depressive Disorder: A Randomized, Double-Blind, Sham-Controlled Clinical Trial
Objective Low-intensity transcranial focused ultrasound (tFUS) has emerged as a promising non-invasive brain stimulation modality with high spatial selectivity and the ability to reach deep brain areas. The present study aimed to investigate the safety and effectiveness of low-intensity tFUS in treating major depressive disorder.Methods Participants were recruited in an outpatient clinic and randomly assigned to either the verum tFUS or sham stimulation group. The intervention group received six sessions of tFUS stimulation to the left dorsolateral prefrontal cortex over two weeks. Neuropsychological assessments were conducted before and after the sessions. Resting-state functional magnetic resonance imaging (rsfMRI) was also performed to evaluate changes in functional connectivity (FC). The primary outcome measure was the change in depressive symptoms, assessed with the Montgomery–Åsberg Depression Rating Scale (MADRS).Results The tFUS stimulation sessions were well tolerated without any undesirable side effects. The analysis revealed a significant main effect of session sequence on the MADRS scores and significant interactions between the session sequences and groups. The rsfMRI analysis showed a higher FC correlation between the right superior part of the subgenual anterior cingulate cortex (sgACC) and several other brain regions in the verum group compared with the sham group.Conclusion Our results reveal that tFUS stimulation clinically improved MADRS scores with network-level modulation of a sgACC subregion. This randomized, sham-controlled clinical trial, the first study of its kind, demonstrated the safety and probable efficacy of tFUS stimulation for the treatment of depression.
- 25 August 2024
- Published by Korean Neuropsychiatric Association in Psychiatry Investigation
- Vol. 21 (8) , 885-896
Open AccessEffect of Low-Intensity Transcranial Focused Ultrasound Stimulation in Patients With Major Depressive Disorder: A Randomized, Double-Blind, Sham-Controlled Clinical Trial
Objective Low-intensity transcranial focused ultrasound (tFUS) has emerged as a promising non-invasive brain stimulation modality with high spatial selectivity and the ability to reach deep brain areas. The present study aimed to investigate the safety and effectiveness of low-intensity tFUS in treating major depressive disorder.Methods Participants were recruited in an outpatient clinic and randomly assigned to either the verum tFUS or sham stimulation group. The intervention group received six sessions of tFUS stimulation to the left dorsolateral prefrontal cortex over two weeks. Neuropsychological assessments were conducted before and after the sessions. Resting-state functional magnetic resonance imaging (rsfMRI) was also performed to evaluate changes in functional connectivity (FC). The primary outcome measure was the change in depressive symptoms, assessed with the Montgomery–Åsberg Depression Rating Scale (MADRS).Results The tFUS stimulation sessions were well tolerated without any undesirable side effects. The analysis revealed a significant main effect of session sequence on the MADRS scores and significant interactions between the session sequences and groups. The rsfMRI analysis showed a higher FC correlation between the right superior part of the subgenual anterior cingulate cortex (sgACC) and several other brain regions in the verum group compared with the sham group.Conclusion Our results reveal that tFUS stimulation clinically improved MADRS scores with network-level modulation of a sgACC subregion. This randomized, sham-controlled clinical trial, the first study of its kind, demonstrated the safety and probable efficacy of tFUS stimulation for the treatment of depression.
- Open Access
- 25 March 2024
- Published by Korean Neuropsychiatric Association in Psychiatry Investigation
- Vol. 21 (3) , 230-241
Exploratory Clinical Trial of a Depression Diagnostic Software That Integrates Stress Biomarkers and Composite Psychometrics
Objective This study evaluated the clinical effectiveness of Minds.NAVI, a depression screening kit combining psychometric measures and stress hormone biomarkers, in a prospective clinical trial. The objective was to assess its potential as a depression screening tool and investigate the associations between psychological assessments, salivary hormone staging, and depression severity.Methods Thirty-five participants with major depressive disorder and 12 healthy controls (HCs) were included. The Minds.NAVI software, utilizing the PROtective and Vulnerable factors battEry Test (PROVE) and salivary cortisol/dehydroepiandrosterone (DHEA) analysis, was employed. The PROVE test is a comprehensive self-report questionnaire that assesses depressive symptoms, suicide risk, attachment style, adverse childhood experiences, mentalization capacity, and resilience. In addition, salivary cortisol and DHEA levels were measured to evaluate the functional stage of the hypothalamic–pituitary–adrenal (HPA) axis.Results Minds.NAVI exhibited 100% sensitivity, 91.7% specificity, and 97.9% accuracy in distinguishing depression from HCs within an exploratory small group. Salivary stress hormone phases showed changes with depression stage (p=0.030), and the proportion of patients with “adrenal exhaustion stage” was higher in the moderate/severe depression group (p=0.038). Protective/vulnerable factors differed significantly between controls and depressed groups (p<0.001). Cortisol awakening response inversely correlated with depressive symptom severity (r=-0.31, p=0.034).Conclusion This study suggested possible clinical effectiveness of Minds.NAVI, a depression screening tool that integrates psychometric measures and stress hormone biomarkers. The findings support the potential association between depression, chronic stress, and HPA axis hyporesponsiveness.
- 25 March 2024
- Published by Korean Neuropsychiatric Association in Psychiatry Investigation
- Vol. 21 (3) , 230-241
Open AccessExploratory Clinical Trial of a Depression Diagnostic Software That Integrates Stress Biomarkers and Composite Psychometrics
Objective This study evaluated the clinical effectiveness of Minds.NAVI, a depression screening kit combining psychometric measures and stress hormone biomarkers, in a prospective clinical trial. The objective was to assess its potential as a depression screening tool and investigate the associations between psychological assessments, salivary hormone staging, and depression severity.Methods Thirty-five participants with major depressive disorder and 12 healthy controls (HCs) were included. The Minds.NAVI software, utilizing the PROtective and Vulnerable factors battEry Test (PROVE) and salivary cortisol/dehydroepiandrosterone (DHEA) analysis, was employed. The PROVE test is a comprehensive self-report questionnaire that assesses depressive symptoms, suicide risk, attachment style, adverse childhood experiences, mentalization capacity, and resilience. In addition, salivary cortisol and DHEA levels were measured to evaluate the functional stage of the hypothalamic–pituitary–adrenal (HPA) axis.Results Minds.NAVI exhibited 100% sensitivity, 91.7% specificity, and 97.9% accuracy in distinguishing depression from HCs within an exploratory small group. Salivary stress hormone phases showed changes with depression stage (p=0.030), and the proportion of patients with “adrenal exhaustion stage” was higher in the moderate/severe depression group (p=0.038). Protective/vulnerable factors differed significantly between controls and depressed groups (p<0.001). Cortisol awakening response inversely correlated with depressive symptom severity (r=-0.31, p=0.034).Conclusion This study suggested possible clinical effectiveness of Minds.NAVI, a depression screening tool that integrates psychometric measures and stress hormone biomarkers. The findings support the potential association between depression, chronic stress, and HPA axis hyporesponsiveness.
- 1 January 2021
- Published by Korean Neuropsychiatric Association in Journal of Korean Neuropsychiatric Association
- Vol. 60 (2) , 143-157
Development of the Battery Test for Screening of Depression and Mental Health: PROtective and Vulnerable factors battEry Test (PROVE)
이주열, et al. J Korean Neuropsychiatr Assoc. 2021 May;60(2):143-157. https://doi.org/10.4306/jknpa.2021.60.2.143
- 1 January 2021
- Published by Korean Neuropsychiatric Association in Journal of Korean Neuropsychiatric Association
- Vol. 60 (2) , 143-157
Development of the Battery Test for Screening of Depression and Mental Health: PROtective and Vulnerable factors battEry Test (PROVE)
이주열, et al. J Korean Neuropsychiatr Assoc. 2021 May;60(2):143-157. https://doi.org/10.4306/jknpa.2021.60.2.143
- Open Access
- 1 January 2021
- Published by Yonsei University College of Medicine in Yonsei Medical Journal
- Vol. 62 (4) , 359-365
Association between BDNF Polymorphism and Depressive Symptoms in Patients Newly Diagnosed with Type 2 Diabetes Mellitus
Ryu JS, et al. Yonsei Med J. 2021 Apr;62(4):359-365. https://doi.org/10.3349/ymj.2021.62.4.359
- 1 January 2021
- Published by Yonsei University College of Medicine in Yonsei Medical Journal
- Vol. 62 (4) , 359-365
Open AccessAssociation between BDNF Polymorphism and Depressive Symptoms in Patients Newly Diagnosed with Type 2 Diabetes Mellitus
Ryu JS, et al. Yonsei Med J. 2021 Apr;62(4):359-365. https://doi.org/10.3349/ymj.2021.62.4.359